348 related articles for article (PubMed ID: 10344751)
41. Synthesis and preclinical evaluation of [11C]D617, a metabolite of (R)-[11C]verapamil.
Verbeek J; Syvänen S; Schuit RC; Eriksson J; de Lange EC; Windhorst AD; Luurtsema G; Lammertsma AA
Nucl Med Biol; 2012 May; 39(4):530-9. PubMed ID: 22226023
[TBL] [Abstract][Full Text] [Related]
42. The multidrug-resistance modifiers verapamil, cyclosporine A and tamoxifen induce an intracellular acidification in colon carcinoma cell lines in vitro.
Hamilton G; Cosentini EP; Teleky B; Koperna T; Zacheri J; Riegler M; Feil W; Schiessel R; Wenzi E
Anticancer Res; 1993; 13(6A):2059-63. PubMed ID: 7905252
[TBL] [Abstract][Full Text] [Related]
43. Analogs of a 4-aminothieno[2,3-d]pyrimidine lead (QB13) as modulators of P-glycoprotein substrate specificity.
Häcker HG; de la Haye A; Sterz K; Schnakenburg G; Wiese M; Gütschow M
Bioorg Med Chem Lett; 2009 Nov; 19(21):6102-5. PubMed ID: 19783433
[TBL] [Abstract][Full Text] [Related]
44. Clinical studies with modulators of multidrug resistance.
Fisher GA; Sikic BI
Hematol Oncol Clin North Am; 1995 Apr; 9(2):363-82. PubMed ID: 7642468
[TBL] [Abstract][Full Text] [Related]
45. Modulators of multidrug resistance. Preclinical studies.
Ford JM
Hematol Oncol Clin North Am; 1995 Apr; 9(2):337-61. PubMed ID: 7642467
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of a method for detection of cells with reduced drug retention in solid tumours.
Carpentier Y; Gorisse MC; Desoize B
Cytometry; 1992; 13(6):630-7. PubMed ID: 1360399
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat.
Luurtsema G; Molthoff CF; Schuit RC; Windhorst AD; Lammertsma AA; Franssen EJ
Nucl Med Biol; 2005 Jan; 32(1):87-93. PubMed ID: 15691665
[TBL] [Abstract][Full Text] [Related]
48. The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake.
Mankhetkorn S; Garnier-Suillerot A
Eur J Pharmacol; 1998 Feb; 343(2-3):313-21. PubMed ID: 9570481
[TBL] [Abstract][Full Text] [Related]
49. The chemosensitizing potential of GF120918 is independent of the magnitude of P-glycoprotein-mediated resistance to conventional chemotherapeutic agents in a small cell lung cancer line.
Myer MS; Joone G; Chasen MR; van Rensburg CE
Oncol Rep; 1999; 6(1):217-8. PubMed ID: 9864431
[TBL] [Abstract][Full Text] [Related]
50. Multidrug resistance of testis cancers: the study of clinical relevance of P-glycoprotein expression.
Eid H; Bodrogi I; Csókay B; Oláh E; Bak M
Anticancer Res; 1996; 16(6B):3447-52. PubMed ID: 9042205
[TBL] [Abstract][Full Text] [Related]
51. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET.
Bankstahl JP; Kuntner C; Abrahim A; Karch R; Stanek J; Wanek T; Wadsak W; Kletter K; Müller M; Löscher W; Langer O
J Nucl Med; 2008 Aug; 49(8):1328-35. PubMed ID: 18632828
[TBL] [Abstract][Full Text] [Related]
52. Expression of apoptosis-related proteins and morphological changes in a rat tumor model of human small cell lung cancer prior to and after treatment with radiotherapy, carboplatin, or combined treatment.
Fokkema E; De Vries EG; Groen HJ; Meijer C; Timens W
Virchows Arch; 2003 Apr; 442(4):349-55. PubMed ID: 12715170
[TBL] [Abstract][Full Text] [Related]
53. Circumvention of multidrug resistance by a quinoline derivative, MS-209, in multidrug-resistant human small-cell lung cancer cells and its synergistic interaction with cyclosporin A or verapamil.
Shrivastava P; Hanibuchi M; Yano S; Parajuli P; Tsuruo T; Sone S
Cancer Chemother Pharmacol; 1998; 42(6):483-90. PubMed ID: 9788575
[TBL] [Abstract][Full Text] [Related]
54. Altered activity of MDR-reversing agents on KB3-1 cells transfected with Gly(185)-->Val human P-glycoprotein.
Watanabe T; Uchiyama N; Roninson IB; Cohen D; Atadja P
Int J Oncol; 2000 Sep; 17(3):579-86. PubMed ID: 10938401
[TBL] [Abstract][Full Text] [Related]
55. Modulation of daunorubicin intracellular accumulation in P-glycoprotein expressing MCF-7 human breast adenocarcinoma cells by thermosensitive-liposome encapsulation and hyperthermia.
Merlin JL; Marchal S; Ramacci C; Notter D; Vigneron C
Int J Hyperthermia; 1995; 11(6):855-65. PubMed ID: 8586906
[TBL] [Abstract][Full Text] [Related]
56. Administration of drugs known to inhibit P-glycoprotein increases brain bilirubin and alters the regional distribution of bilirubin in rat brain.
Hankø E; Tommarello S; Watchko JF; Hansen TW
Pediatr Res; 2003 Oct; 54(4):441-5. PubMed ID: 12904601
[TBL] [Abstract][Full Text] [Related]
57. Dynamic and intracellular trafficking of P-glycoprotein-EGFP fusion protein: Implications in multidrug resistance in cancer.
Fu D; Bebawy M; Kable EP; Roufogalis BD
Int J Cancer; 2004 Mar; 109(2):174-81. PubMed ID: 14750166
[TBL] [Abstract][Full Text] [Related]
58. (R)-[11C]verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus.
Syvänen S; Luurtsema G; Molthoff CF; Windhorst AD; Huisman MC; Lammertsma AA; Voskuyl RA; de Lange EC
BMC Med Imaging; 2011 Jan; 11():1. PubMed ID: 21199574
[TBL] [Abstract][Full Text] [Related]
59. Locally increased P-glycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood-brain barrier.
de Klerk OL; Willemsen AT; Roosink M; Bartels AL; Hendrikse NH; Bosker FJ; den Boer JA
Int J Neuropsychopharmacol; 2009 Aug; 12(7):895-904. PubMed ID: 19224656
[TBL] [Abstract][Full Text] [Related]
60. Multidrug resistance-modifying components in human plasma with potential clinical significance.
Mülder HS; Pinedo HM; Timmer AT; Rao BR; Lankelma J
J Exp Ther Oncol; 1996 Jan; 1(1):13-22. PubMed ID: 9414384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
